

REMARKS

In the specification, the paragraph on page 183, describing the preparation of Example A(153), has been amended to correct an obvious error in the name of the example. That the original name is an error is clear from the structure of the compound shown and the remainder of Example A(153) in which the precursor compound prepared in Step 1 is substituted with a fluoro group instead of a chloro group. Furthermore, the structure of the intermediate shown in Step 1 of Example A(153) shows that the aryl ring contains a fluorine substituent. Further support for this name change is found in the originally-filed specification in Example A(117) at page 145. As such, no new matter has been added.

Claims 1-4 have been canceled herein without prejudice. Applicants hereby expressly reserve the right to prosecute claims to the canceled subject matter in future applications.

Claim 5 has been rewritten to put it into independent form. As such, no new matter has been added.


Claims 27, 28, and 29 have been amended to make the names of the claimed compounds consistent with the names found in original Examples A(116), A(117) and newly amended Example A(153). Support for these amendments is found in Examples A(116) and A(117), found at pages 144-145 of the originally filed specification. As such, no new matter has been added.

Claims 30, 31, and 32 have been amended to claim methods of using compounds according to claim 5 instead of canceled claim 1. Support for this amendment is found at page 23 of the originally filed specification. As such, no new matter has been added.

Applicant respectfully requests entry of the foregoing amendments and allowance of the remaining claims.

Respectfully submitted,

Date: May 18, 2004

  
\_\_\_\_\_  
Jeffrey J. Tidwell  
Attorney For Applicant  
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-3877  
Fax: (858) 678-8233